Revolutionizing Ophthalmic Surgery with Programmable Synthetic Biomaterials

BioOptix is led by a multidisciplinary team of expert ophthalmologists, scientists, and business leaders with deep experience in clinical practice, R&D, operations, and venture investment. We believe that advancing ophthalmic surgical technology can profoundly improve outcomes for millions of patients around the world.

Our vision is better vision.

Optimatrix™ OVD

Biocompatible, Instantly Dissolvable, and Sustainably Engineered

Since the introduction of OVDs in the 1980s, most innovations have focused on incremental changes to naturally derived materials. Optimatrix™ represents a true leap forward: a fully synthetic, programmable biomaterial that combines cohesive and dispersive properties in a single formulation. It dissolves instantly with cold saline, simplifying removal and reducing postoperative risks—addressing core limitations that have persisted for over four decades.

Optimatrix™ Features

Fully Synthetic & Programmable

Ophthalmic biomaterial combining cohesive and dispersive properties, with a viscoelastic profile tailored to each stage of surgery.

Instant Dissolution

Transforms from gel to liquid with cold saline for complete removal—minimizing risk of postoperative complications.

Clinically Safe

Biocompatible, biodegradable, and non-immunogenic with supporting safety data from analogous orthopedic and dental uses.

Protected Innovation

Backed by over 40 granted patents, securing IP coverage through 2039 and beyond.

Sustainable By Design

Cartilage-free and synthetically manufactured, avoiding the ecological impact of shark-derived OVDs.

* The products and technologies described on this website have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Information provided is for research, informational, and investigational purposes only.

Our Team

Dr. Yuna Rapoport

CEO & Founder

- Leading ophthalmic surgeon
- Founder of Manhattan Eye, ophthalmological l practice focusing on cataract, glaucoma and corneal diseases of the eye
- Product Market Fit, Fundraising, Clinical Trials, Growth

Alex Goldberg

Board Member

- General Partner and Co-Founder at AdAstral Funds
- Serial entrepreneur with several large exits
- Role: business advisor

Gary Berman

Advisor

- Seasoned healthcare executive with over 20 years of experience building and scaling therapeutics companies
- Led the advancement of innovative treatments across multiple therapeutic areas, including ophthalmology, and CEO of Tavo Biotherapeutics
- Role: brainstorming, growth

Dr. Ali Fathi

CSO, Science Advisory Board

- Biomedical entrepreneur and inventor, specializing in material science
- Founder and CTO of Tetratherix, a biomed startup with over 40granted patents and significant funding
- Role: Lead of polymer execution, product execution, safety data

Johnnie Walker

CFO

- Co-Founder of Rooled, which provides outsourced accounting, fractional CFO, and tax services to venture-backed and high-growth companies
- Role: CFO

Will Knox

Advisor

- Leads commercial development of medical technologies and healthcare innovations
- Bridges the worlds of medical devices, consumer e-commerce, private investing and wearable technologies
- CEO, Tertratherix
- Role: Strategy of growth of BioOptix with IP from Tetraherix; business advisor

Maurizio Vecchione

Board Member

- Co-founder and Co-General partner of AdAstral Funds
- President and CEO of Washington Global Health Alliance
- Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation
- EVP for Global Good and Research at Intellectual Ventures
- Role: Growth and brainstorming

Lee Kramm

VP Regulatory (Consulting)

- President of RPG
- Has led multiple pharmaceutical projects including R&D transformation
- Senior reviewer at DONED at FDA
- Role: Advisor for regulatory compliance for clinical trials and for FDA submission

Investment Inquiries

Press Inquiries